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The human epigenetic cell-cycle regulator HCF-1
undergoes an unusual proteolytic maturation
process resulting in stably associated HCF-1N
and HCF-1C subunits that regulate different aspects
of the cell cycle. Proteolysis occurs at six cen-
trally located HCF-1PRO-repeat sequences and is
important for activation of HCF-1C-subunit func-
tions in M phase progression. We show here that
the HCF-1PRO repeat is recognized by O-linked b-N-
acetylglucosamine transferase (OGT), which both
O-GlcNAcylates the HCF-1N subunit and directly
cleaves the HCF-1PRO repeat. Replacement of the
HCF-1PRO repeats by a heterologous proteolytic
cleavage signal promotes HCF-1 proteolysis but fails
to activateHCF-1C-subunitMphase functions. These
results reveal an unexpected role of OGT in HCF-1
proteolytic maturation and an unforeseen nexus
between OGT-directedO-GlcNAcylation and proteo-
lytic maturation in HCF-1 cell-cycle regulation.INTRODUCTION
The informational complexity of organisms can be greatly
enhanced by the posttranslational modification of proteins.
Modifications that involve the addition of a chemical group,
such as phosphorylation, acetylation, methylation, glycosyla-
tion, and ubiquitination, are generally reversible, whereas modi-
fication by proteolytic processing is considered irreversible. The
variety of modification forms and their regulatory outcomes
provides diverse strategies for the control of protein function.
Among modifications involving the addition of a chemical
group, glycosylation is themost abundant (Nalivaeva and Turner,
2001) and, of the different types of glycosylation, the monoaddi-
tion of O-linked b-N-acetylglucosamine (O-GlcNAc) moieties on
serine and threonine residues is the most important to regulate
the function of metazoan cytosolic and nuclear proteins (Torres376 Cell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc.and Hart, 1984; Wells and Hart, 2003). The broad presence of
O-GlcNAc-modified proteins involved in many fundamental
cellular processes, including cell morphogenesis, cell signaling,
apoptosis, and transcription, suggests important physiological
roles for O-GlcNAcylation (Lazarus et al., 2006). O-GlcNAcyla-
tion exhibits similarities to phosphorylation, such as common
target residues (i.e., serines and threonines), proteins, and
dynamic nature (Hart et al., 2007; Wells and Hart, 2003; Wells
et al., 2001), but differs in that O-GlcNAcylation is achieved by
a single cellular enzyme: O-GlcNAc transferase (OGT) (Halti-
wanger et al., 1992).
OGT is a ubiquitously expressed and conserved enzyme that
uses the donor substrate UDP-GlcNAc for glycosylation. It is
composed of two important regions: an N-terminal 13.5 tetratri-
copeptide-repeat (TPR) superhelical structure (Jinek et al.,
2004), involved in substrate recognition (Lubas and Hanover,
2000), and a C-terminal catalytic domain (Kreppel and Hart,
1999). The catalytic domain contains the UDP-GlcNAc binding
site but the precise mechanism of O-GlcNAc transfer to
substrates is not known (Clarke et al., 2008; Martinez-Fleites
et al., 2008). OGT forms stable associations with numerous
proteins, such as the histone acetyltransferase MOF (Cai et al.,
2010), the protein phosphatase PP1 (Wells et al., 2004), the
transcriptional corepressor Sin3A (Yang et al., 2002), and the
cell-cycle regulator HCF-1 (Wysocka et al., 2003; Mazars et al.,
2010), the subject of this study.
HCF-1 is a transcriptional coregulator conserved among
animal species that was first discovered as a host-cell factor
for human herpes simplex virus infection (Kristie et al., 2010;
Wysocka and Herr, 2003). In vertebrates, HCF-1 undergoes an
unusual process of proteolytic maturation. It is synthesized as
a large precursor protein that is subsequently cleaved at a series
of six centrally located 26 amino acid repeats called HCF-1PRO
(PRO for proteolysis) repeats. The resulting heterogeneous
collection of N- (HCF-1N) and C- (HCF-1C) terminal subunits
remains noncovalently associated (Kristie et al., 1995; Wilson
et al., 1993, 1995). An important cellular function of human
HCF-1 is the regulation of the cell cycle: the HCF-1N subunit
promotes passage through the G1 phase (Goto et al., 1997;
Julien and Herr, 2003; Tyagi and Herr, 2009) and the HCF-1C
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Figure 1. Sequence and In Vitro Mutational Analysis of HCF-1PRO Repeats
(A) Schematic representation of the human HCF-1 protein and sequence alignment of the six human HCF-1PRO repeats. The black arrowhead indicates the
cleavage site.
(B) HCF-1PRO-repeat sequence conservation. WebLogo (Crooks et al., 2004) was obtained by the alignment of all HCF-1PRO repeats from six different species:
human, mouse, Xenopus tropicalis, X. laevis, Fugu rubripes, and Danio rerio.
(C) In vitro alanine-scan mutagenesis. The wild-type HCF-1PROrep2 precursor (lane 0) as well as individual HCF-1PROrep2 alanine mutants (lanes 1–19, 21, 22, and
24–26) were incubated with HeLa nuclear extract. The gray arrowheads indicate the positions of the two HCF-1PROrep2 alanines that were not mutated. The
precursor (–) and the visible N-terminal cleavage product (d) are indicated. Colored dots indicate mutations with strong (blue) or intermediate (cyan) effects on
either in vitro or in vivo (Wilson et al., 1995) cleavage.subunit ensures proper mitosis and cytokinesis in M phase
(Julien and Herr, 2003, 2004). Interestingly, HCF-1 proteolytic
maturation is necessary to activate human HCF-1C-subunit
function in M phase (Julien and Herr, 2003).
Curiously, themechanism of HCF-1 proteolyticmaturation has
diverged in evolution. Whereas HCF-1PRO-repeat-dependent
HCF-1 maturation is apparently shared by, and restricted to, all
vertebrate species, in some invertebrate species (e.g.,
Drosophila) HCF-1 homologs also undergo proteolytic matura-
tion but by a different mechanism involving the protease
Taspase1 (Capotosti et al., 2007). In vertebrates, Taspase1 is
responsible for proteolytic maturation of the mixed-lineage
leukemia (MLL) histone methyltransferase protein (Hsieh et al.,
2003) but not of HCF-1 (Capotosti et al., 2007). How
HCF-1PRO-repeat-dependent proteolytic maturation is achievedremains to be clarified, as evidence supporting both autocata-
lytic (Vogel and Kristie, 2000) and nonautocatalytic (Capotosti
et al., 2007) mechanisms has been reported.
We demonstrate here a connection between HCF-1PRO-
repeat-inducedHCF-1proteolyticmaturationandOGT,providing
an unexpected linkbetween reversible and irreversible posttrans-
lational modification pathways to control protein function.
RESULTS
The HCF-1PRO Repeat Represents an Elaborate
Cleavage Signal
Figure 1A shows the close similarity among the six human
HCF-1PRO repeats and the site of proteolytic cleavage, a glutamic
acid at position 10 (E10) (arrowhead; Kristie et al., 1995; WilsonCell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc. 377
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Figure 2. O-GlcNAcylation Is Important for HCF-1PRO-Repeat Cleavage
(A) Schematic representation of full-length HCF-1 and HCF-1rep123.
(B) Inhibition of HCF-1PRO-repeat cleavage. HCF-1rep123 synthesized in RRL was incubated with buffer (lane 1), HeLa nuclear extract (NE; lane 2), or NE
pretreated with alloxan (lane 3) or staurosporine (lane 4).
(C) OGT depletion by siRNA. 293 cells were either mock treated (lane 1) or treatedwith luciferase- (Luc; lane 2) or OGT- (lane 3) specific siRNAs. OGT and a-tubulin
(aTub.) levels were visualized by immunoblot.
(D) Effect of OGT depletion on HCF-1PRO-repeat cleavage. Cells treated as in (C) were transiently transfected with the HCF-rep123 (lanes 1–3) and HCF-1repXXX
(lanes 4–6) expression constructs. Precursor cleavage was analyzed by a-HA tag immunoblot. The bracket indicates the O-GlcNAc-modified HCF-1rep123
precursor. Empty and filled arrowheads indicate the O-GlcNAc-modified HCF-1rep123 precursor and HCF-1PRO-repeat 1 cleavage product, respectively.
Asterisks indicate nonspecific bands.
In (B) and (D), precursor proteins (–) and cleavage products (d) are indicated.et al., 1993, 1995). A sequence logo generated from a multiple
vertebrate species alignment highlights the extensive conserva-
tion of the HCF-1PRO repeats (Figure 1B).
For a protease recognition sequence, the HCF-1PRO repeat is
large. Indeed, in vivo assay of a complete set of HCF-1PRO-
repeat 2 alanine-scan mutants revealed an 18 amino acid core
required for full cleavage activity (Wilson et al., 1995). Using
a previously described humanHeLa cell extract assay (Capotosti
et al., 2007), we tested cleavage of the same set of alanine-scan
mutants in vitro, as shown in Figure 1C. The effect of the alanine
substitutions was very similar to what was previously observed
in vivo (Figure 1C), indicating that the in vitro assay faithfully
reflects normal HCF-1 proteolytic maturation. The mutational
analysis revealed a C-terminal HCF-1PRO-repeat region with
a number of conserved and functionally important threonine
residues. We refer to this region as the ‘‘threonine region’’ and
the sequences surrounding the cleavage site as the ‘‘cleavage
region’’ (see Figure 1C).378 Cell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc.A Role for OGT in HCF-1PRO-Repeat Proteolysis
In Vitro and In Vivo
Three observations led us to ask whether protein modification
might be important for HCF-1PRO-repeat cleavage: (1) the
resistance of the HeLa cell proteolytic activity to fractionation,
suggesting multiple components (F.C. and W.H., unpublished
results); (2) a retarded electrophoretic mobility of the uncleaved
HCF-1PRO-repeat precursor after in vitro cleavage reaction
(Capotosti et al., 2007), a property often indicative of posttrans-
lational modification; and (3) the critical threonine region
given that threonines can be sites for phosphorylation and
O-GlcNAcylation. We therefore tested whether a general inhib-
itor of phosphorylation (staurosporine) or of O-GlcNAcylation
(alloxan) affects processing in vitro of the HCF-1-derived
precursor called HCF-1rep123 (Figure 2A). As shown in Fig-
ure 2B, alloxan, but not staurosporine, reduced HCF-1rep123
cleavage (compare lanes 3 and 4 with lane 2), suggesting a rela-
tionship between O-GlcNAcylation and HCF-1PRO-repeat
cleavage and a possible role of OGT in HCF-1 proteolytic
maturation.
To test this hypothesis, we asked whether depletion of OGT
in vivo affectsHCF-1rep123processing.OGTcanbesignificantly
depleted after 48 hr of human 293 cell treatment with an OGT-
specific (lane 3) but not an irrelevant (lane 2) siRNA duplex (Fig-
ure 2C). We assayed the effect of OGT depletion on cleavage of
the wild-type HCF-1rep123 precursor and an HCF-1repXXX
mutant with alanine-substituted E10 cleavage-site residues
(E10A), synthesizedduring the last 24 hr of 48 hr siRNA treatment.
HCF-1repXXX was not affected by OGT depletion (Figure 2D,
lanes4–6). In contrast,withHCF-1rep123,OGTdepletion caused
a specific (compare lanes 1–3) reduction of the HCF-1PRO-repeat
1 cleavage product (filled arrowhead) and of a slowermigrating—
possibly modified—form of the precursor (open arrowhead).
(Note that the products of HCF-1PRO-repeat 2 and 3 cleavage
are obscured by other species in this experiment.) Together,
these results suggest a role for OGT and possibly O-GlcNAcyla-
tion in proteolytic processing of HCF-1.
The HCF-1rep123 Precursor Is O-GlcNAcylated
in an HCF-1PRO-Repeat-Dependent Manner
To test for a link between O-GlcNAcylation and proteolysis,
we assayed glycosylation of HCF-1rep123 and HCF-1repXXX,
together with the HCF-1PRO-repeat 1-containing HCF-1rep1XX
protein, in vivo. After synthesis in 293 cells, a-HA tag immuno-
purified recombinant proteins (Figure 3Aa) were probed
for O-GlcNAcylation by immunoblot (Figure 3Ab). Consistent
with HCF-1PRO-repeat-dependent O-GlcNAcylation, the HCF-
1rep123 and HCF-1rep1XX, but not HCF-1repXXX, precur-
sors and cleavage products were readily recognized by the
a-O-GlcNAc antibody (Figure 3Ab; lanes 1–3). The slower migra-
tion of the precursor observed here and in Figure 2D (see
brackets) probably results from the O-GlcNAcylation as
opposed to phosphorylation, as it was insensitive to phospha-
tase treatment (see Figure S1 available online). The HCF-1PRO-
repeat dependence of HCF-1rep123 O-GlcNAcylation was
unexpected because we had hypothesized that glycosylation
might activate HCF-1rep123 proteolysis, not that the HCF-1PRO
repeat might activate HCF-1rep123 glycosylation.
HCF-1PRO Repeats Can Induce Multiple O-GlcNAc
Modifications in the HCF-1N Subunit
HCF-1 is O-GlcNAcylated (Wilson et al., 1993; Wysocka et al.,
2003) at multiple sites (Mazars et al., 2010; Wang et al., 2010).
Here wemappedO-GlcNAcylation sites in purified HCF-1rep123
and HCF-1repXXX precursors after in vivo synthesis. The
HCF-1rep123 material (Figure 3B, lane 1) produced a doublet
of faster- (a) and slower- (a0) migrating forms upon silver staining.
In contrast, with HCF-1repXXX, the faster-migrating form (b)
predominated (lane 2). These three polypeptides were individu-
ally analyzed by tandem mass spectrometry, and glycosylated
and nonglycosylated peptides were identified and quantified
(see Table S1). Figure 3C shows the results for one peptide
(HCF-1 residues 724–770). This peptide from samples a and b
was predominantly unmodified, whereas from sample a0 it was
predominantly O-GlcNAcylated, consistent with HCF-1PRO-
repeat-dependent HCF-1 O-GlcNAcylation.Figure 3D shows the results of our HCF-1rep123 O-GlcNAc
modification mapping, together with sites mapped by Wang
et al. (2010) within this region. Interestingly, the mapped sites
exclude the HCF-1PRO-repeats but include extensive N-terminal
O-GlcNAc modifications. Thus, counter to our aforementioned
rationale, the HCF-1PRO-repeat threonine region is apparently
not O-GlcNAc modified.
To obtain a global appreciation of HCF-1O-GlcNAcylation, we
analyzed O-GlcNAcylation of endogenous HCF-1, as shown in
Figure 3E. Immunopurified endogenous HCF-1 was subjected
to immunoblot analysis with antibodies specific to either
the HCF-1C or HCF-1N subunit, or O-GlcNAc (lanes 1–3). The
resulting O-GlcNAc staining pattern matches the HCF-1N but
not the HCF-1C (lane 4)-subunit profile, suggesting that HCF-1
O-GlcNAcylation is largely limited to the HCF-1N subunit (see
also Mazars et al., 2010; Wang et al., 2010).
OGT Recognizes the HCF-1PRO Repeat
The dependence of HCF-1O-GlcNAcylation on active HCF-1PRO
repeats led us to ask whether the HCF-1PRO repeat also
promotes OGT binding to HCF-1. Analysis of the HCF-1rep123
immunoprecipitates from Figure 3A (see also Figure 4Aa)
showed that OGT—present in the original extracts (Fig-
ure 4Ab)—was present in the HCF-1rep123 but not mock
samples (Figure 4Ac, compare lanes 1 and 4). Indeed, OGT
bound even better to the HCF-1rep1XX and HCF-1repXXX
precursors carrying the E10A cleavage-site mutation (lanes 2
and 3). Thus, curiously, although inhibiting HCF-1PRO-repeat
cleavage and HCF-1rep123 glycosylation, the E10A mutation
enhancesOGT association with the HCF-1PRO-repeat precursor.
These results led us to ask whether OGT association with
HCF-1 can be mediated by the HCF-1PRO repeat. For this, we
tested OGT association with full-length HCF-1 and the four
HCF-1 mutants illustrated in Figure 4B: (1) HCF-1PROMUT
carrying the E10A cleavage-site mutation in all six HCF-1PRO
repeats (the HCF-1nc mutant of Vogel and Kristie, 2006); (2)
HCF-1DPRO, lacking the HCF-1PRO-repeat region (Wilson et al.,
1995), and (3) HCF-1DPROrep2 and (4) HCF-1DPROrep2E10A carrying
a single wild-type or mutated HCF-1PRO repeat 2. Figure 4C
shows the (1) levels of wild-type and mutant HCF-1 synthesis
after transient expression (Figure 4Ca), (2) levels of endogenous
OGT (Figure 4Cb), and (3) levels of OGT coprecipitated with the
various HCF-1 proteins (Figure 4Cc). As with the HCF-1rep123
proteins, OGT was recovered with full-length HCF-1 and signifi-
cantly better with HCF-1PROMUT (lanes 2 and 3). Furthermore, the
E10A HCF-1DPROrep2E10A mutant bound OGT better than its wild-
type HCF-1DPROrep2 counterpart (lanes 5 and 6). In contrast,
there was no evident OGT association in the absence of an
HCF-1PRO repeat (see HCF-1DPRO; lane 4). These results indicate
that the HCF-1PRO-repeat sequence itself is the target for OGT
binding and that the E10A mutation improves binding.
Threonine-Region Mutations Disrupt OGT Association
with HCF-1PRO Repeat 2
The E10A HCF-1PRO-repeat substitution lies within the HCF-
1PRO-repeat cleavage region. To test the effect of mutations in
the threonine region, we assayed endogenous OGT association
with wild-type or mutated HCF-1PRO repeats (repeat 2)Cell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc. 379
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Figure 3. Analysis of HCF-1rep123 O-GlcNAcylation
(A) HCF-1PRO-repeat-dependent HCF-1rep123O-GlcNAcylation. 293 cells were mock transfected (lane 4), or transfected with different HCF-1rep123 expression
vectors (lanes 1–3; see Figure 2A). a-HA immunoprecipitated proteins were visualized by a-HA tag (panel a) or a-O-GlcNAc (panel b) immunoblot. Precursor
proteins (–), cleavage products (d), and O-GlcNAc-modified proteins (bracket) are indicated. The asterisk indicates an immunoglobulin heavy chain. See also
Figure S1.
(B) Purification of HCF-1PRO-repeat precursors. HCF-1rep123 (lane 1) and HCF-1repXXX (lane 2) were synthesized in 293 cells, immunoprecipitated, and
visualized by silver staining. Different HCF-1rep123 (a and a0) and HCF-1repXXX (b) forms are indicated.
(C) Relative abundance of peptides corresponding to HCF-1 residues 724–770 with 0, 1, 2, or 3O-GlcNAc moieties attached in samples a, a0, and b from (B) (gray
boxes indicate the predominant peptide species for each sample; see Table S1 for the complete list of O-GlcNAcylated peptides).
(D) Schematic representation ofmapped HCF-1rep123O-GlcNAc sites. HCF-1rep123 regions covered by theMS analysis are indicated below the diagram. Filled
and empty squares indicate certain or potential O-GlcNAcylation residues, respectively. Yellow dots indicate Wang et al. (2010)-identified O-GlcNAcylated
residues.
(E) Endogenous HCF-1 O-GlcNAcylation. HCF-1 was immunoprecipitated from 293 cells with the C18 a-HCF-1 antibody and visualized by H12 (lane 1), N13
(lane 2), a-O-GlcNAc (lane 3), or combined H12 and a-O-GlcNAc (lane 4) immunoblot. Regions recognized by the different a-HCF-1 antibodies are indicated
below.
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Figure 4. Interaction between OGT and the HCF-1PRO Repeats
(A) OGT coimmunoprecipitation with wild-type and mutant HCF-1PRO-repeat constructs. Immunoprecipitated samples from Figure 3A (and reshown in panel a)
were probed for OGT coimmunoprecipitation as described below. IP, immunoprecipitate; TI, total input.
(B) Schematic representation of different HCF-1PRO-repeat mutants. Dots indicate E10A-mutated HCF-1PRO repeats.
(C) OGT interactionwith HCF-1PRO-repeat mutants. 293 cells weremock transfected (lane 1) or transfectedwith the different HCF-1PRO-repeat mutant constructs
(lanes 2–6). Unlabeled bands represent nonspecific species. In (A) and (C), precursor proteins (–) and cleavage products (d) are indicated.
(D) Effect of mutations in HCF-1PRO repeat 2 on interaction with OGT. 293 cells were mock transfected (lane 1), or transfected with a wild-type (lane 2) or mutated
(lanes 3–5) Oct-1/rep2 precursor with the indicated HCF-1PROrep2.
In (A), (C), and (D), immunoprecipitated samples were visualized by a-HA tag (panel a) and a-OGT (panel c) immunoblot. Total input (TI) samples visualized by
a-OGT immunoblot are shown in panel b.embedded in the heterologous protein Oct-1 (Oct-1/rep2;
Wilson et al., 1995) as shown in Figure 4D. In this assay, wild-
type HCF-1PRO-repeat 2–OGT interaction was not detectable
(lane 2), but the E10A mutation increased OGT association suffi-
ciently to make it clearly detectable (lane 3). In contrast, alanine
substitution of four essential threonines (T17, T19, T21, and T22)
in the threonine region (T17–22 mutation) did not increase OGT
HCF-1PRO-repeat binding (lane 4), and indeed inhibited binding
when combined as a double mutant with the E10A mutation
(compare lanes 3 and 5). Thus, OGT association with the
HCF-1PRO repeat is influenced bymutations in both the cleavage
and threonine regions.
OGT Cleaves the HCF-1PRO Repeat In Vitro
The aforementioned results suggest that OGT has an intimate
role in HCF-1PRO-repeat cleavage. To define this role further,we began by testing the ability of recombinant human OGT
(rhOGT) purified after synthesis in either insect Sf9 cells (Inssynt)
or Escherichia coli (Bacsynt) (see Figures S2A and S2B) to induce
in vitro cleavage of the HCF-1rep123 precursor in the presence
of the OGT cofactor UDP-GlcNAc. As shown in Figure 5A (lanes
1–3), both these rhOGT preparations can cleave the
HCF-1rep123 precursor synthesized by in vitro translation in
a rabbit reticulocyte lysate (RRL). (The HCF-1rep123 fragment
mobility difference in lanes 2 and 3 probably reflects the greater
O-GlcNAc transferase activity of the Inssynt versus Bacsynt
rhOGT) (Figure S2C). In the RRL, the HCF-1rep123 precursor is
O-GlcNAcylated during synthesis (data not shown). To avoid
this glycosylation, we synthesized the precursor in a plant wheat
germ extract (WGE) which lacksOGT activity (Starr andHanover,
1990). This precursor was also effectively cleaved by the rhOGT
preparations (compare lanes 4–6 and 1–3), showing thatCell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc. 381
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Figure 5. Recombinant OGT Is Sufficient to Induce
HCF-1PRO-Repeat Cleavage In Vitro
(A) Recombinant human OGT (rhOGT) cleavage of in vitro
synthesized HCF-1PRO-repeat precursors. The HCF-
1rep123 precursor was synthesized in vitro using RRL
(lanes 1–3) or WGE (lanes 4–6) and incubated with buffer
(lanes 1 and 4), or rhOGT synthesized and purified from
insect cells (Inssynt; lanes 2 and 5) or from bacterial cells
(Bacsynt; lanes 3 and 6). See also Figures S2A–S2C.
(B) rhOGT cleavage of a bacterially synthesized HCF-
1PRO-repeat precursor. The GST-HCF-1rep1 precursor
(see schematic) synthesized in and purified from bacteria
and incubated without (lane 1) or with (lane 2) Bacsynt
rhOGT. HCF-1PRO-repeat 1 cleavage was analyzed by
a-GST immunoblot. The asterisk indicates an N-terminal
precursor truncation and the bracket indicates the
O-GlcNAc-modified form of the precursor. See also Fig-
ure S2D.
(C) rhOGT HCF-1PRO-repeat cleavage characterization.
GST-HCF-1rep1 precursors containing wild-type (WT) or
E10A-mutated HCF-1PRO repeat 1 were subjected to
in vitro cleavage in the presence (+) or absence (–) of the
indicated factors. The asterisk indicates an N-terminal
precursor truncation.
(D) rhOGT cleavage of HCF-1PRO-repeat 2 alanine-scan
mutants. The analysis was performed as in Figure 1C using
Bacsynt rhOGT and WGE synthesized precursors. Dots
indicate mutations with strong (blue) and intermediate
(cyan) effects on cleavage. The results with HeLa
cell nuclear extract (NE) from Figure 1C are shown for
reference.
(E) Schematic representation of full-length (flOGT), trun-
cated, and alanine-substitution rhOGT constructs.
(F) The wild-type and indicated OGT mutants were
synthesized and purified from E. coli and then visualized by
a-OGT immunoblot (panel a). The O-GlcNAc transferase
activity of rhOGT molecules was determined by OGT
self-glycosylation and CKII O-GlcNAcylation using the
a-O-GlcNAc antibody (panel b). Proteolytic activity was
determined by HCF-1rep123 in vitro cleavage (panel c).
The asterisk indicates a nonspecific band.
In (A)–(D) and (F), the precursor proteins (–) and cleavage
products (d) are indicated.precursor O-GlcNAcylation prior to the cleavage reaction is not
required for HCF-1PRO-repeat cleavage.
These results led us to test for HCF-1PRO-repeat cleavage by
OGT directly. To this end, we used an HCF-1PRO-repeat
substrate and OGT both synthesized in and purified from
bacteria. Owing to the insolubility of the HCF-1rep123 precursor
synthesized in bacteria, we designed the smaller HCF-1
precursor illustrated in Figure 5B spanning a single HCF-1PRO
repeat 1 (either wild-type or E10A mutant) fused to GST
(GST-HCF-1rep1). As shown in Figure 5B, Bacsynt OGT cleaved
(as well as O-GlcNAcylated; Figure S2D) the wild-type
GST-HCF-1rep1 precursor, showing that OGT itself induces
HCF-1PRO-repeat cleavage.
OGT Glycosylation Activity Is Important
for HCF-1PRO-Repeat Cleavage
To probe the importance of the O-GlcNAcylation activity of
OGT for HCF-1PRO-repeat proteolysis, we determined the382 Cell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc.dependence of proteolysis on the UDP-GlcNAc cofactor
and its sensitivity to an OGT inhibitor. As shown in Figure 5C,
both Bacsynt (lane 1) and Inssynt (lane 7) OGT were active on
the bacterially synthesized wild-type (top), but not E10A point
mutant (bottom), HCF-1rep1 precursor, but removal of either
UDP-GlcNAc or OGT prevented cleavage (top, lanes 2 and 3).
The requirement for two components—OGT and its UDP-
GlcNAc cofactor—for HCF-1PRO-repeat proteolysis explains
the resistance of the HeLa cell HCF-1PRO-repeat proteolytic
activity to fractionation.
Alloxan, used to inhibitO-GlcNAcylation in Figure 2B, is a rela-
tively nonspecific inhibitor that apparently mimics the uracil
moiety of the UDP-GlcNAc cofactor (Konrad et al., 2002).
Here, to inactivate OGT glycosylation, we additionally used the
more specific inhibitor ST078925 (Gross et al., 2005), which
also inhibited HCF-1PRO-repeat proteolysis (compare lane 1
with lanes 4 and 5). In contrast, as described previously for the
HeLa cell activity (Capotosti et al., 2007), OGT-induced
ArhOGT:   –    0'   30'  1h   2h   4h   8h
sHCF-1ΔPROrep2HCF-1PRO-repeat proteolysis is resistant to the serine protease
inhibitor Pefabloc (lane 6), showing that it differs from the
HCF-1 autocatalytic activity described byVogel and Kristie (2000).     1     2     3     4     5      6     7
 –OGT HCF-1PRO-Repeat Cleavage Is Dependent
on the Complete HCF-1PRO-Repeat Signal
In Figure 5D, we show that the Bacsynt rhOGT cleavage pattern of
the set of 24 HCF-1PRO-repeat 2 alanine-scan mutants synthe-
sized in WGE is essentially the same as that with the HeLa cell
nuclear extract (compare with Figure 1C). Thus, OGT itself
appears to recognize the large HCF-1PRO-repeat signal and to
reproduce entirely the HeLa cell proteolytic activity.
B
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Figure 6. The O-GlcNAc Modification of the HCF-1PRO-Repeat
Precursor Is Not Sufficient to Induce Proteolysis
(A) Time course of sHCF-1DPROrep2 precursor treatment with Bacsynt rhOGT.
(B) OGT inhibition during sHCF-1DPROrep2 cleavage. The sHCF-1DPROrep2
precursor was treated as indicated in the schematic experimental flow chart
(top). The sHCF-1DPROrep2 precursor synthesized in WGE was incubated with
Bacsynt rhOGT without (lanes 2 and 4) or with (lanes 3 and 5) addition of alloxan
(Alx) and terminated at the times indicated.
Precursor protein (–), both cleavage products (d), and O-GlcNAc-modified
proteins (brackets) are indicated. See also Figure S3.Both the TPR and Catalytic Domains of OGT
Are Important for HCF-1PRO-Repeat Proteolysis
To identify elements of OGT required for HCF-1PRO-repeat
proteolysis, we assayed the activities of a set of Bacsynt rhOGT
mutants previously characterized for O-GlcNAc transferase
activity on either heterologous substrates or for self-glycosyla-
tion (Clarke et al., 2008; Gross et al., 2005; Hanover et al.,
2003; Martinez-Fleites et al., 2008). As shown in Figure 5E, we
analyzed two truncations: one containing the TPR region and
one corresponding to an OGT splice variant (sOGT) lacking
most of the TPR region (Hanover et al., 2003). We also analyzed
three OGT alanine-substitution mutants (Clarke et al., 2008):
N458A between the TPR and catalytic domain (CD); R637A in
the CD; and D925A in the UDP-GlcNAc binding pocket.
Bacsynt wild-type and mutant rhOGT proteins (Figure 5Fa)
were tested for their O-GlcNAc transferase activity on the
heterologous substrate casein kinase II (CKII) as well as by
self-glycosylation (Figure 5Fb). Only the wild-type and N458A
mutant displayed evident CKII O-GlcNAc transferase activity
(Figure 5Fb, lanes 2 and 5). Consistent with its reported activities
(Hanover et al., 2003; Clarke et al., 2008), the sOGT protein did
not exhibit CKII O-GlcNAc transferase activity but displayed
enhanced self-glycosylation activity (Figures 5Fa and 5Fb,
compare lanes 7 and 2), whereas the TPR mutant was inactive.
Among the set of rhOGT mutants, there was a perfect correla-
tion between the ability to O-GlcNAcylate the heterologous CKII
substrate and to induce HCF-1rep123 proteolysis (Figure 5Fc). In
contrast, there was not such a correlation with self-glycosylation
activity, as the sOGT form did not display HCF-1rep123 proteo-
lytic activity (Figures 5Fb and 5Fc, lane 7). These results suggest
(1) that both the TPR and CD regions of OGT are required for
HCF-1PRO-repeat proteolysis and (2) that residues involved in
O-GlcNAc transferase activity are important for HCF-1PRO-
repeat proteolysis.OGT-Induced O-GlcNAcylation Is Not Sufficient
to Induce HCF-1PRO-Repeat Proteolysis
Although OGT appears to induce HCF-1PRO-repeat proteolysis
on its own, the aforementioned studies do not discriminate
between whether (1) OGT O-GlcNAcylation of HCF-1 induces
HCF-1PRO-repeat autoproteolysis or (2) OGT possesses a previ-
ously unrecognized site-specific proteolytic activity that can
induce cleavage of the HCF-1PRO repeats either entirely on its
own or in collaboration with the HCF-1PRO repeat.To discriminate between these two possibilities, we devel-
oped an assay in which glycosylation and proteolysis could
be clearly monitored simultaneously. This assay takes advan-
tage of a ‘‘short’’ version, called sHCF-1DPROrep2, of the
HCF-1DPROrep2 precursor shown in Figure 4B; it exhibits a clear
electrophoretic mobility shift upon O-GlcNAcylation (see Fig-
ure S3). As shown in Figure 6A, with this precursor, within
a 30 min incubation with the Bacsynt rhOGT (lane 3), a retarded
O-GlcNAcylated form is apparent (indicated by the bracket).
This O-GlcNAc-modified precursor increased for up to 2 hr
and then slowly disappeared as two cleavage products accumu-
lated—a slower-migrating N-terminal and faster-migrating
C-terminal cleavage product (indicated by dots). We used the
clear appearance of both O-GlcNAcylated precursor andCell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc. 383
cleavage products to probe the direct or indirect role of OGT in
HCF-1PRO-repeat proteolysis.
We used alloxan to block OGT activity at different time points
and then examined the effects on HCF-1PRO-repeat proteolysis.
We initiated a series of sHCF-1DPROrep2 cleavage reactions by
addition of OGT (see Figure 6B, top). OGT was then inactivated
by addition of alloxan at either the start of the reaction (0 hr),
which prevented its function throughout the experiment (lane
5), or after 1 hr, at which point there was initial sHCF-1DPROrep2
precursor O-GlcNAcylation but little cleavage (lane 3). Two
control reactions were terminated at 1 hr (lane 2) or 8 hr
(lane 4) without the addition of alloxan. These control reactions
showed that, after 1 hr, the O-GlcNAcylated precursor and
some cleavage products appeared (compare lanes 2 and 1)
and, after 8 hr, the cleavage products became more abundant
whereas theO-GlcNAcylated precursor did not (lane 4). Addition
of alloxan after 1 hr (lane 3) resulted in arresting the reaction such
that after 8 hr the O-GlcNAcylation and cleavage pattern were
essentially identical to that after 1 hr (compare lanes 2–4).
Thus, there is no apparent cleavage of the O-GlcNAcylated
sHCF-1DPROrep2 precursor in the absence of OGT function.
These results suggest that theO-GlcNAcylated HCF-1 precursor
is not potentiated for independent autoproteolysis. We conclude
that OGT possesses a proteolytic activity which may be wholly
contained within OGT or function in intimate collaboration with
the HCF-1PRO repeat (see Discussion).
A Heterologous Protease Cleavage Site Fails
to Restore HCF-1C-Subunit Function
Given the evident unusual nature of HCF-1 proteolytic matura-
tion, we asked whether this specific process is important for
the HCF-1C-subunit function in M phase (see Introduction). For
this, we replaced the HCF-1PRO-repeat region with the two
natural Taspase1 protease cleavage sites found in MLL (Hsieh
et al., 2003) to create HCF-1DPROMLL (see Figure 7A). Given that
Taspase1 naturally cleaves the Drosophila HCF-1 homolog, this
experiment addresses whether the appearance of HCF-1PRO-
repeat-induced HCF-1 maturation was evolutionarily significant.
We first tested for OGT interaction with the HCF-1DPROMLL
mutant. As shown in Figure 7B, HCF-1DPROMLL is effectively
cleaved in 293 cells (Figure 7Ba, lane 4) but, like HCF-1DPRO, is
defective for OGT binding (Figure 7Bc, lanes 2–4). Thus, replace-
ment of the HCF-1PRO repeats with the MLL Taspase1 cleavage
sites separates HCF-1 proteolysis from evident OGT binding.
We then asked whether the HCF-1DPROMLL protein is able to
rescue the M phase binucleation defect induced by loss of
HCF-1 processing (Julien and Herr, 2003). We produced a cell
line expressing an siRNA-resistant HCF-1DPROMLL protein, selec-
tively depleted the endogenous HCF-1 protein by siRNA, and
counted the number of binucleated cells. As shown in Figure 7C,
only the wild-type full-length HCF-1 (WT) and to a lesser extent
the HCF-1C subunit (C600) but not the HCF-1DPRO protein were
able to rescue the binucleation phenotype induced by the lost
of endogenous HCF-1. (The inability of the HCF-1DPRO protein
to rescue the binucleation phenotype is not owing to the absence
of the HCF-1PRO-repeat region per se because the HCF-1PROMUT
protein shown in Figure 4B also displays binucleation defects;
S.G. and W.H., unpublished results.) Interestingly, the cleaved384 Cell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc.HCF-1DPROMLL protein is not able to rescue the binucleation
defect, suggesting that HCF-1PRO-repeat-mediated HCF-1
proteolytic maturation—and probably HCF-1N O-GlcNAcyla-
tion—are important to activate the M phase functions of the
HCF-1C subunit.
DISCUSSION
We have investigated the mechanisms of HCF-1 proteolytic
maturation and identified a link between OGT-induced HCF-1
proteolysis and O-GlcNAcylation. OGT binds and cleaves the
HCF-1PRO repeats while inducing O-GlcNAcylation of the HCF-
1N subunit. This link is associated with activation of the M phase
regulatory functions of HCF-1. These activities of OGT connect
the class of reversible posttranslational modifications such as
glycosylation with essentially irreversible proteolytic processing.
How we arrived at these conclusions was circuitous. We
began by hypothesizing that HCF-1PRO-repeat cleavage
involves modification of a series of highly conserved and impor-
tant threonines. Indeed, modification—O-GlcNAcylation—is
important, but the HCF-1PRO repeat is apparently not the target
of this modification. Instead, it is the binding site for OGT, which
then promotes O-GlcNAcylation elsewhere as well as cleavage
of its own binding site.
A Bipartite Association of OGT
with the HCF-1PRO Repeat
The analysis of OGT binding to the HCF-1PRO repeat suggests
that it recognizes both the cleavage and threonine regions:
thus, OGT displays enhanced association with a cleavage-
region mutant (E10A), and a threonine-region mutant (T17–22A)
counteracts this enhancement (see Figure 4). The inhibition of
OGT association by the threonine-region mutant suggests that
OGT does not recognize and bind the cleavage region effectively
on its own. We suggest that the threonine region represents
a site for stable OGT interaction. The enhanced association of
OGT with the E10A mutant was not expected. Given that the
E10 residue is immediately adjacent to the cleavage site, we
suggest that this residue associates with the catalytic center of
OGT. If OGT association with the HCF-1PRO repeat is reduced
upon proteolytic cleavage, then inhibition of cleavage by the
E10A mutation could enhance OGT binding to the HCF-1PRO
repeat by retaining OGT on the noncleavable site. Thus, OGT
is essentially ‘‘trapped’’ on the E10A mutant.
We find intriguing the bipartite TPR and CD structure of OGT
and the bipartite threonine and cleavage structure of the HCF-
1PRO repeat. We suggest a one-to-one correspondence
between the OGT TPR region and HCF-1PRO-repeat threonine
region for binding and OGT CD region and HCF-1PRO-repeat
cleavage region for HCF-1PRO-repeat proteolysis. This hypoth-
esis can explain the surprisingly large sequence required for
HCF-1PRO-repeat-induced proteolysis.
Although we initiated our studies hypothesizing that the threo-
nine region would serve as a site for modification to activate
HCF-1PRO-repeat proteolysis, we now imagine that the inverse
might be true: O-GlcNAcylation of the threonine region inhibits
OGT binding to the HCF-1PRO repeat, which could be used to
inhibit HCF-1 proteolytic maturation.
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Figure 7. OGT-Mediated HCF-1PRO-Repeat Proteolysis Is Important for HCF-1C Function
(A) Schematic representation of different HCF-1 recombinants. CS1 and CS2 indicate the two Taspase1 cleavage sites of the MLL protein (Hsieh et al., 2003).
(B) OGT association assay with HCF-1 protein carrying the MLL Taspase1 sites. Lanes 1–3 are as shown in Figure 4C. Lane 4: 293 cells transfected with the
HCF-1DPROMLL construct. Immunoprecipitated samples were visualized by a-HA tag (panel a) and a-OGT (panel c) immunoblot. Total input (TI) samples were
visualized by a-OGT immunoblot (panel b). Precursor proteins (–) and cleavage products (d) are indicated.
(C) Quantification of binucleated cells in the parental Flp-In-HeLa cells as well as in the indicated cell lines after control (Luc; green) or HCF-1 (red/orange) siRNA
(data are represented as mean ± SD). In orange is indicated the background level of binucleation for each sample. The percentages below the histogram indicate
differences between the Luc and HCF-1 siRNA for each sample.
(D) Proposed model for OGT-induced HCF-1PRO-repeat proteolytic maturation showing potential consequences for HCF-1-protein conformation and function
(see text). Kelch indicates an N-terminal Kelch-repeat domain.
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OGT: An Unusual Protease
The large sequence required for HCF-1PRO-repeat-induced
proteolysis had suggested that the HCF-1PRO repeat would be
cleaved by an unusual mechanism. The discovery that OGT is
responsible for HCF-1PRO-repeat cleavage is consistent with
this hypothesis.
We imagine two principal ways in which OGT might cleave the
HCF-1PRO repeat: OGT could possess a catalytic center for
proteolysis or function as a coprotease to cleave HCF-1 in
collaboration with the HCF-1PRO repeat. Relative to the first
hypothesis, we have not been able to identify a protease-like
domain. Nevertheless, OGT is distantly related to enzymes
that, like proteases, are hydrolases (Wrabl and Grishin, 2001),
and thus OGT might possess an unusual proteolytic catalytic
center.
In the second preferred hypothesis, OGT functions in intimate
collaboration with the HCF-1PRO repeat for cleavage. For
example, OGT might stimulate HCF-1PRO-repeat cleavage simi-
larly to E. coli RecA-induced autocleavage of the LexA repressor
(Luo et al., 2001). Here, RecA binding to LexA induces a confor-
mational change of LexA, allowing for a repositioning of the LexA
active and cleavage sites for autocleavage. By analogy, OGT
binding to the HCF-1PRO repeatmight lead to a change in confor-
mation that stimulates hydrolysis, for example by activating the
essential E10 residue at the cleavage site. We also imagine
that GlcNAc moieties on HCF-1 could in turn play a specific
role in cleavage. For example, GlcNAc could be bound by—or
remain bound to—OGT via its UDP-GlcNAc pocket and, as
such, either directly (e.g., participate in catalysis) or indirectly
(e.g., play a conformational role) stimulate HCF-1PRO-repeat
cleavage. Such a mechanism could ensure coordinate HCF-1
O-GlcNAcylation and cleavage.A Proteolytic Cleavage Signal Regulates
Posttranslational Modification: A Model for HCF-1
Maturation
Proteolytic maturation of HCF-1 was known to be important for
the biological functions of HCF-1. It is now evident that HCF-1
proteolytic maturation involves not only proteolysis but also
O-GlcNAc modification, and that the interplay between these
two modifications is what appears to regulate HCF-1 function
in M phase. We propose in Figure 7Da a three-step mechanism
for HCF-1 maturation: OGT (1) associates with the elaborate
HCF-1PRO-repeat signal, (2) O-GlcNAcylates the HCF-1N
subunit, and (3) cleaves the protein. In contrast, we suggest
that Taspase1-induced HCF-1 cleavage circumvents the
O-GlcNAcylation step (Figure 7Db) and that this step is critical
for activation of the HCF-1C subunit for M phase progression.
The HCF-1N basic and HCF-1C acidic regions are known to
associate noncovalently with one another (Wilson et al., 2000).
Perhaps repeated O-GlcNAc modification within and around
the HCF-1N basic region induced by the presence of multiple
HCF-1PRO repeats disrupts this HCF-1N and HCF-1C interaction,
functionally liberating transcriptional activation (in orange;
Luciano and Wilson, 2002) and chromatin association (in red;
Julien and Herr, 2004) domains present in the HCF-1C acidic
region.386 Cell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc.Why Involve OGT in HCF-1 Maturation?
OGT has been hypothesized to serve as a sensor for the meta-
bolic state of the cell by responding to glucose levels (Butkinaree
et al., 2010; Love et al., 2010). Because HCF-1 promotes cell
proliferation and cell proliferation is associated with enhanced
nutrient supplies that generate glucose, we suggest that a
role for OGT in activation of HCF-1 via proteolytic maturation
involving O-GlcNAcylation can link the cellular activities of
HCF-1 to the metabolic state of the cell.
EXPERIMENTAL PROCEDURES
Plasmid Constructs and DNA Template Preparation
Plasmids and DNA templates are described in Extended Experimental
Procedures.
Cell Culture, Extract Preparation, and Plasmid and siRNA
Transfections
Human HeLa and 293 cells were grown on plates at 37C in DMEM with 10%
FBS. Nuclear extracts for in vitro cleavage assay were prepared from spinner
HeLa cells as previously described (Dignam et al., 1983). Plasmid and siRNA
transfections were performed with Lipofectamine or Oligofectamine, respec-
tively, as described (Invitrogen) (see also Extended Experimental Procedures).
Synthesis and Purification of Recombinant Proteins from Bacterial
and Insect Cells
For GST–HCF-1rep1WT and GST–HCF-1rep1E10A synthesis in E. coli, BL21
(DE5) cells were grown at 22C until an OD600 of 0.6 before induction with
0.4 mM IPTG for 4 hr. Cells were lysed with PBS supplemented with lysozyme,
and lysateswere centrifuged at 13,0003 g for 30min. SDSwas added to a final
concentration of 1% and lysates were boiled for 10 min. SDS was then diluted
to 0.1% with PBS and the lysates were incubated with Ni beads overnight at
4C. Proteins were eluted with 500 mM imidazole and dialyzed against PBS.
Wild-type and mutant S-tagged human OGTs were synthesized in E. coli
BL21(DE5) cells. Cells were grown at 25C until an OD600 of 0.6, at which point
OGT synthesis was induced with 0.4 mM IPTG and cells were incubated at
16C for 16 hr. The OGT proteins were purified using the S-tag purification
system, as recommended (Novagen). Wild-type Flag-tagged OGT was
synthesized in insect Sf9 cells, lysates were prepared, and proteins were
immunoprecipitated using immobilized a-Flag magnetic beads (Sigma) and
eluted using 0.2mg/ml of 13 Flag peptide as described (Cai et al., 2006, 2010).
In Vitro Cleavage and O-GlcNAc Transferase Assays
In vitro HCF-1PRO-repeat cleavage was performed in 100 mMHEPES (pH 7.9),
5 mM MgCl2, 20 mM KCl, 5 mM DTT, and 10% sucrose at a final volume of
30 ml at 37C for 16 hr or as specified (Capotosti et al., 2007; Hsieh et al.,
2003). For the rhOGT in vitro cleavage assay, 1.5 mg of Inssynt or Bacsynt rhOGT
preparation was used and the cleavage buffer was supplemented with 5 mM
UDP-GlcNAc. The presence of DTT was critical for OGT-induced HCF-1PRO-
repeat cleavage. Bacterially purified GST-HCF-1rep1 in vitro cleavage was
performed with 500 ng precursor protein. For inhibitor treatment, reactions
prior to precursor addition were treated for 30 min at RT with either 2.5 mM
alloxan (Konrad et al., 2002), 15 mM staurosporine (Gani and Engh, 2010),
0.5 mg/ml Pefabloc (Vogel and Kristie, 2000), or 500 mM ST078925. The
ST078925 inhibitor (4-[(3-cyano-4-(2-thienyl)-2-5,6,7,8-tetrahydroquino-
lylthio)methyl] benzoic acid; TimTec) is an analog substitute of the validated
inhibitor 6 fromGross et al. (2005). For phosphatase treatment, in vitro cleaved
HCF-1repXX3 precursor was incubated for 2 hr at 37C with 400 U of l phos-
phatase (PPase) in the absence or presence of 50 mM EDTA. The O-GlcNAc
transferase assay was performed as described (Clarke et al., 2008) using
2500 U of the CKII substrate.
Nondenaturating Immunoprecipitation
For a-HA tag immunoprecipitation, cells were lysed in 0.5% NP40, 10 mM
TrisCl (pH 8.0), 150 mM NaCl, 5 mM MgCl2 (NP40 buffer; Misaghi et al.,
2009). Lysates were incubated with a-HA agarose beads (Sigma) overnight at
4C, beads were washed extensively in NP40 buffer, and immunoprecipitated
material was eluted in SDS-PAGE loading buffer. For endogenous HCF-1
immunoprecipitation, 1.5 mg of 420 mM KCl HeLa nuclear extract was diluted
to 100 mM KCl and incubated overnight at 4C with 10 ml of C18 a-HCF-1C
antibody or 10 ml of nonimmune sera. Samples were analyzed by immunoblot.
See Extended Experimental Procedures for the origin of antibodies used and
procedure for immunoblot analysis.O-GlcNAcylation Analysis by LC-MS/MS
HA-tagged HCF-1rep123 plasmid expression vectors were transfected into
ten 15 cm dishes of 293 cells for 48 hr. Cells were lysed in 8 ml NP40 buffer.
The lysates were adjusted to 1% SDS and boiled for 10 min. The SDS concen-
tration was subsequently adjusted to 0.1% by dilution with NP40 buffer, and
lysates were incubated with a-HA agarose beads overnight at 4C. For proteo-
mic analysis, see Extended Experimental Procedures.Generation of Cell Lines and Binucleation Analysis
To create the recombinant HCF-1 Flp-In-HeLa cells, 0.4 mg of pCDNA5/HA-
FLAG/FRT vector containing genes of interest was cotransfected with 3.6 mg
of the Flpase expression vector pOG44 into Flp-In-HeLa cells (a kind gift of
S.S. Taylor) with Lipofectamine, and transfected cells were selected in
hygromycin-containing medium (300 mg/ml) for 10 days as described (Invitro-
gen). Three independent clones for each recombinant HCF-1 construct were
selected for analysis. Endogenous HCF-1 was depleted by double siRNA
treatment for 50 hr and binucleated cells were quantitated by staining with
a-tubulin and a-HCF-1C H12—to determine HCF-1 depletion—antibodies
and DAPI as previously described (Julien and Herr, 2003). One hundred cells
were counted per siRNA depletion and each independent clone was analyzed
in triplicate. Data were summarized as mean ± standard deviation (SD).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, three
figures, and one table and can be found with this article online at doi:10.1016/
j.cell.2010.12.030.ACKNOWLEDGMENTS
We thank T.M. Kristie and J.A. Hanover for the HCF-1nc and the bacterial OGT
expression vectors, respectively; M. Boutros and A. Wilson for the HCF-
1DPROrep2 construct; R.S. Haltiwanger for the a-OGT antibody; E. Julien and
D.J. Aufiero for the N13 and C18 antibodies; S.S. Taylor for the Flp-In-HeLa
cells; M. Quadroni for advice with the mass spectrometry analysis; L. Capponi,
P. L’Hoˆte, and M. McLaird for technical support; and J.H. Reina for art design.
We thank N. Hernandez, J. Michaud, and S.H. Verhelst for critical reading
of the manuscript; and V. Zoete, O. Michielin, N. Hernandez, J. Mu¨ller,
P. Schneider, and K. Struhl for discussion. This study was supported by the
Stowers Institute for Medical Research and the Helen Nelson Medical
Research Fund at the Greater Kansas City Community Foundation to J.W.C.
and R.C.C. and by the Swiss National Science Foundation, Oncosuisse, and
the University of Lausanne to W.H.
Received: August 20, 2010
Revised: November 22, 2010
Accepted: December 16, 2010
Published: February 3, 2011REFERENCES
Butkinaree, C., Park, K., and Hart, G.W. (2010). O-linked b-N-acetylglucos-
amine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate
signaling and transcription in response to nutrients and stress. Biochim.
Biophys. Acta 1800, 96–106.Cai, Y., Jin, J., Gottschalk, A.J., Yao, T., Conaway, J.W., and Conaway, R.C.
(2006). Purification and assay of the human INO80 and SRCAP chromatin
remodeling complexes. Methods 40, 312–317.
Cai, Y., Jin, J., Swanson, S.K., Cole, M.D., Choi, S.H., Florens, L., Washburn,
M.P., Conaway, J.W., and Conaway, R.C. (2010). Subunit composition and
substrate specificity of a MOF-containing histone acetyltransferase distinct
from the male-specific lethal (MSL) complex. J. Biol. Chem. 285, 4268–4272.
Capotosti, F., Hsieh, J.J., and Herr, W. (2007). Species selectivity of mixed-
lineage leukemia/trithorax and HCF proteolytic maturation pathways. Mol.
Cell. Biol. 27, 7063–7072.
Clarke, A.J., Hurtado-Guerrero, R., Pathak, S., Schuttelkopf, A.W., Borodkin,
V., Shepherd, S.M., Ibrahim, A.F., and van Aalten, D.M. (2008). Structural
insights into mechanism and specificity of O-GlcNAc transferase. EMBO J.
27, 2780–2788.
Crooks, G.E., Hon, G., Chandonia, J.M., and Brenner, S.E. (2004). WebLogo:
a sequence logo generator. Genome Res. 14, 1188–1190.
Dignam, J.D., Lebovitz, R.M., and Roeder, R.G. (1983). Accurate transcription
initiation by RNA polymerase II in a soluble extract from isolated mammalian
nuclei. Nucleic Acids Res. 11, 1475–1489.
Gani, O.A., and Engh, R.A. (2010). Protein kinase inhibition of clinically impor-
tant staurosporine analogues. Nat. Prod. Rep. 27, 489–498.
Goto, H., Motomura, S., Wilson, A.C., Freiman, R.N., Nakabeppu, Y.,
Fukushima, K., Fujishima, M., Herr, W., and Nishimoto, T. (1997). A single-
point mutation in HCF causes temperature-sensitive cell-cycle arrest and
disrupts VP16 function. Genes Dev. 11, 726–737.
Gross, B.J., Kraybill, B.C., and Walker, S. (2005). Discovery of O-GlcNAc
transferase inhibitors. J. Am. Chem. Soc. 127, 14588–14589.
Haltiwanger, R.S., Blomberg, M.A., and Hart, G.W. (1992). Glycosylation of
nuclear and cytoplasmic proteins. Purification and characterization of a uridine
diphospho-N-acetylglucosamine:polypeptide b-N-acetylglucosaminyltrans-
ferase. J. Biol. Chem. 267, 9005–9013.
Hanover, J.A., Yu, S., Lubas, W.B., Shin, S.H., Ragano-Caracciola, M.,
Kochran, J., and Love, D.C. (2003). Mitochondrial and nucleocytoplasmic
isoforms of O-linked GlcNAc transferase encoded by a single mammalian
gene. Arch. Biochem. Biophys. 409, 287–297.
Hart, G.W., Housley, M.P., and Slawson, C. (2007). Cycling of O-linked b-N-
acetylglucosamine on nucleocytoplasmic proteins. Nature 446, 1017–1022.
Hsieh, J.J., Cheng, E.H., and Korsmeyer, S.J. (2003). Taspase1: a threonine
aspartase required for cleavage of MLL and proper HOX gene expression.
Cell 115, 293–303.
Jinek, M., Rehwinkel, J., Lazarus, B.D., Izaurralde, E., Hanover, J.A., and
Conti, E. (2004). The superhelical TPR-repeat domain of O-linked GlcNAc
transferase exhibits structural similarities to importin a. Nat. Struct. Mol.
Biol. 11, 1001–1007.
Julien, E., and Herr, W. (2003). Proteolytic processing is necessary to separate
and ensure proper cell growth and cytokinesis functions of HCF-1. EMBO J.
22, 2360–2369.
Julien, E., and Herr, W. (2004). A switch in mitotic histone H4 lysine 20 meth-
ylation status is linked to M phase defects upon loss of HCF-1. Mol. Cell 14,
713–725.
Konrad, R.J., Zhang, F., Hale, J.E., Knierman, M.D., Becker, G.W., and
Kudlow, J.E. (2002). Alloxan is an inhibitor of the enzymeO-linked N-acetylglu-
cosamine transferase. Biochem. Biophys. Res. Commun. 293, 207–212.
Kreppel, L.K., and Hart, G.W. (1999). Regulation of a cytosolic and nuclear
O-GlcNAc transferase. Role of the tetratricopeptide repeats. J. Biol. Chem.
274, 32015–32022.
Kristie, T.M., Pomerantz, J.L., Twomey, T.C., Parent, S.A., and Sharp, P.A.
(1995). The cellular C1 factor of the herpes simplex virus enhancer complex
is a family of polypeptides. J. Biol. Chem. 270, 4387–4394.
Kristie, T.M., Liang, Y., and Vogel, J.L. (2010). Control of a-herpesvirus IE gene
expression by HCF-1 coupled chromatin modification activities. Biochim.
Biophys. Acta 1799, 257–265.Cell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc. 387
Lazarus, B.D., Love, D.C., and Hanover, J.A. (2006). Recombinant O-GlcNAc
transferase isoforms: identification of O-GlcNAcase, yes tyrosine kinase, and
tau as isoform-specific substrates. Glycobiology 16, 415–421.
Love, D.C., Krause, M.W., and Hanover, J.A. (2010). O-GlcNAc cycling:
emerging roles in development and epigenetics. Semin. Cell Dev. Biol. 21,
646–654.
Lubas, W.A., and Hanover, J.A. (2000). Functional expression of O-linked
GlcNAc transferase. Domain structure and substrate specificity. J. Biol.
Chem. 275, 10983–10988.
Luciano, R.L., and Wilson, A.C. (2002). An activation domain in the C-terminal
subunit of HCF-1 is important for transactivation by VP16 and LZIP. Proc. Natl.
Acad. Sci. USA 99, 13403–13408.
Luo, Y., Pfuetzner, R.A., Mosimann, S., Paetzel, M., Frey, E.A., Cherney, M.,
Kim, B., Little, J.W., and Strynadka, N.C. (2001). Crystal structure of LexA:
a conformational switch for regulation of self-cleavage. Cell 106, 585–594.
Martinez-Fleites, C., Macauley, M.S., He, Y., Shen, D.L., Vocadlo, D.J., and
Davies, G.J. (2008). Structure of an O-GlcNAc transferase homolog provides
insight into intracellular glycosylation. Nat. Struct. Mol. Biol. 15, 764–765.
Mazars, R., Gonzalez-de-Peredo, A., Cayrol, C., Lavigne, A.C., Vogel, J.L.,
Ortega, N., Lacroix, C., Gautier, V., Huet, G., Ray, A., et al. (2010). The
THAP-zinc finger protein THAP1 associates with coactivator HCF-1 and
O-GlcNAc transferase: a link between DYT6 and DYT3 dystonias. J. Biol.
Chem. 285, 13364–13371.
Misaghi, S., Ottosen, S., Izrael-Tomasevic, A., Arnott, D., Lamkanfi,M., Lee, J.,
Liu, J., O’Rourke, K., Dixit, V.M., and Wilson, A.C. (2009). Association of
C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle
regulator host cell factor 1. Mol. Cell. Biol. 29, 2181–2192.
Nalivaeva, N.N., and Turner, A.J. (2001). Post-translational modifications of
proteins: acetylcholinesterase as a model system. Proteomics 1, 735–747.
Starr, C.M., and Hanover, J.A. (1990). Glycosylation of nuclear pore protein
p62. Reticulocyte lysate catalyzes O-linked N-acetylglucosamine addition
in vitro. J. Biol. Chem. 265, 6868–6873.
Torres, C.R., and Hart, G.W. (1984). Topography and polypeptide distribution
of terminal N-acetylglucosamine residues on the surfaces of intact lympho-
cytes. Evidence for O-linked GlcNAc. J. Biol. Chem. 259, 3308–3317.
Tyagi, S., and Herr, W. (2009). E2F1 mediates DNA damage and apoptosis
through HCF-1 and the MLL family of histone methyltransferases. EMBO J.
28, 3185–3195.
Vogel, J.L., and Kristie, T.M. (2000). Autocatalytic proteolysis of the transcrip-
tion factor-coactivator C1 (HCF): a potential role for proteolytic regulation of
coactivator function. Proc. Natl. Acad. Sci. USA 97, 9425–9430.388 Cell 144, 376–388, February 4, 2011 ª2011 Elsevier Inc.Vogel, J.L., and Kristie, T.M. (2006). Site-specific proteolysis of the transcrip-
tional coactivator HCF-1 can regulate its interaction with protein cofactors.
Proc. Natl. Acad. Sci. USA 103, 6817–6822.
Wang, Z., Udeshi, N.D., Slawson, C., Compton, P.D., Sakabe, K., Cheung,
W.D., Shabanowitz, J., Hunt, D.F., and Hart, G.W. (2010). Extensive crosstalk
between O-GlcNAcylation and phosphorylation regulates cytokinesis. Sci.
Signal. 3, ra2.
Wells, L., and Hart, G.W. (2003). O-GlcNAc turns twenty: functional implica-
tions for post-translational modification of nuclear and cytosolic proteins
with a sugar. FEBS Lett. 546, 154–158.
Wells, L., Vosseller, K., and Hart, G.W. (2001). Glycosylation of nucleocyto-
plasmic proteins: signal transduction and O-GlcNAc. Science 291, 2376–
2378.
Wells, L., Kreppel, L.K., Comer, F.I., Wadzinski, B.E., and Hart, G.W. (2004).
O-GlcNAc transferase is in a functional complex with protein phosphatase 1
catalytic subunits. J. Biol. Chem. 279, 38466–38470.
Wilson, A.C., LaMarco, K., Peterson, M.G., and Herr, W. (1993). The VP16
accessory protein HCF is a family of polypeptides processed from a large
precursor protein. Cell 74, 115–125.
Wilson, A.C., Peterson, M.G., and Herr, W. (1995). The HCF repeat is an
unusual proteolytic cleavage signal. Genes Dev. 9, 2445–2458.
Wilson, A.C., Boutros, M., Johnson, K.M., and Herr, W. (2000). HCF-1 amino-
and carboxy-terminal subunit association through two separate sets of inter-
action modules: involvement of fibronectin type 3 repeats. Mol. Cell. Biol.
20, 6721–6730.
Wrabl, J.O., and Grishin, N.V. (2001). Homology between O-linked
GlcNAc transferases and proteins of the glycogen phosphorylase superfamily.
J. Mol. Biol. 314, 365–374.
Wysocka, J., and Herr, W. (2003). The herpes simplex virus VP16-induced
complex: the makings of a regulatory switch. Trends Biochem. Sci. 28,
294–304.
Wysocka, J., Myers, M.P., Laherty, C.D., Eisenman, R.N., and Herr, W. (2003).
Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4
methyltransferase are tethered together selectively by the cell-proliferation
factor HCF-1. Genes Dev. 17, 896–911.
Yang, X., Zhang, F., and Kudlow, J.E. (2002). Recruitment of O-GlcNAc
transferase to promoters by corepressor mSin3A: coupling protein
O-GlcNAcylation to transcriptional repression. Cell 110, 69–80.
